These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30826349)

  • 21. Neuromelanic pigment in substantia nigra neurons of rats and dogs.
    DeMattei M; Levi AC; Fariello RG
    Neurosci Lett; 1986 Dec; 72(1):37-42. PubMed ID: 3492690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcium dynamics control K-ATP channel-mediated bursting in substantia nigra dopamine neurons: a combined experimental and modeling study.
    Knowlton C; Kutterer S; Roeper J; Canavier CC
    J Neurophysiol; 2018 Jan; 119(1):84-95. PubMed ID: 28978764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis.
    Jellinger K; Kienzl E; Rumpelmair G; Riederer P; Stachelberger H; Ben-Shachar D; Youdim MB
    J Neurochem; 1992 Sep; 59(3):1168-71. PubMed ID: 1494904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain.
    Zecca L; Shima T; Stroppolo A; Goj C; Battiston GA; Gerbasi R; Sarna T; Swartz HM
    Neuroscience; 1996 Jul; 73(2):407-15. PubMed ID: 8783258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunohistochemical study of CART-peptide in striato-nigral projections at dopamine loss].
    Romanova IV; Chesnokova AIu; Mikhrina AL
    Ross Fiziol Zh Im I M Sechenova; 2012 Aug; 98(8):980-9. PubMed ID: 23155622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron, the substantia nigra and related neurological disorders.
    Snyder AM; Connor JR
    Biochim Biophys Acta; 2009 Jul; 1790(7):606-14. PubMed ID: 18778755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the axon initial segment of mice substantia nigra dopaminergic neurons.
    González-Cabrera C; Meza R; Ulloa L; Merino-Sepúlveda P; Luco V; Sanhueza A; Oñate-Ponce A; Bolam JP; Henny P
    J Comp Neurol; 2017 Nov; 525(16):3529-3542. PubMed ID: 28734032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits.
    Beach TG; Sue LI; Walker DG; Lue LF; Connor DJ; Caviness JN; Sabbagh MN; Adler CH
    Acta Neuropathol; 2007 Oct; 114(4):419-24. PubMed ID: 17639428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of electroacupuncture intervention on levels of SOD, GSH, GSH-Px, MDA, and apoptosis of dopaminergic neurons in substantia Nigra in rats with Parkinson's disease].
    Li J; Wang LN; Xiao HL; Li X; Yang JJ
    Zhen Ci Yan Jiu; 2014 Jun; 39(3):185-91. PubMed ID: 25069193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A critical review of the function of neuromelanin and an attempt to provide a unified theory.
    Nicolaus BJ
    Med Hypotheses; 2005; 65(4):791-6. PubMed ID: 15949901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP?
    Herrero MT; Hirsch EC; Kastner A; Ruberg M; Luquin MR; Laguna J; Javoy-Agid F; Obeso JA; Agid Y
    Neuroscience; 1993 Sep; 56(2):499-511. PubMed ID: 8247275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for specific phases in the development of human neuromelanin.
    Fedorow H; Halliday GM; Rickert CH; Gerlach M; Riederer P; Double KL
    Neurobiol Aging; 2006 Mar; 27(3):506-12. PubMed ID: 15916835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemistry of neuromelanin.
    Van Woert MH; Ambani LM
    Adv Neurol; 1974; 5():215-23. PubMed ID: 4374063
    [No Abstract]   [Full Text] [Related]  

  • 36. [
    Coakeley S; Cho SS; Koshimori Y; Rusjan P; Ghadery C; Kim J; Lang AE; Houle S; Strafella AP
    Brain Struct Funct; 2018 Mar; 223(2):589-595. PubMed ID: 28884232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuromelanin and Parkinson's disease.
    Marsden CD
    J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo.
    Kim HW; Choi WS; Sorscher N; Park HJ; Tronche F; Palmiter RD; Xia Z
    Neurobiol Aging; 2015 Sep; 36(9):2617-27. PubMed ID: 26070241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for a glycidic-lipidic matrix in human neuromelanin, potentially responsible for the enhanced iron sequestering ability of substantia nigra.
    Aime S; Fasano M; Bergamasco B; Lopiano L; Valente G
    J Neurochem; 1994 Jan; 62(1):369-71. PubMed ID: 8263538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability.
    Zucca FA; Bellei C; Giannelli S; Terreni MR; Gallorini M; Rizzio E; Pezzoli G; Albertini A; Zecca L
    J Neural Transm (Vienna); 2006 Jun; 113(6):757-67. PubMed ID: 16755380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.